ME Therapeutics Holdings Management
Management criteria checks 2/4
ME Therapeutics Holdings' CEO is Salim Dhanji, appointed in Mar 2023, has a tenure of 2.25 years. total yearly compensation is CA$50.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 15.94% of the company’s shares, worth CA$41.75M. The average tenure of the management team and the board of directors is 2.3 years and 2.3 years respectively.
Key information
Salim Dhanji
Chief executive officer
CA$50.0k
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | 2.3yrs |
| CEO ownership | 15.9% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.3yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Feb 28 2025 | n/a | n/a | -CA$1m |
| Nov 30 2024 | n/a | n/a | -CA$1m |
| Aug 31 2024 | CA$50k | CA$50k | -CA$1m |
Compensation vs Market: Salim's total compensation ($USD36.39K) is below average for companies of similar size in the Canadian market ($USD754.84K).
Compensation vs Earnings: Insufficient data to compare Salim's compensation with company performance.
CEO
Salim Dhanji
Dr. Salim Zulifkar Dhanji is Chief Executive Officer and Director of ME Therapeutics Holdings Inc. from March 9, 2023 and is the founder of ME Therapeutics. Dr. Dhanji is a former director of preclinical r...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | CA$50.00k | 15.94% CA$ 41.8m | |
| Chief Financial Officer | 2.3yrs | CA$37.50k | no data | |
| Corporate Secretary | 2.3yrs | no data | 1.53% CA$ 4.0m | |
| Chief Business Officer | less than a year | no data | no data |
Experienced Management: METX's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | CA$50.00k | 15.94% CA$ 41.8m | |
| Director | 2.3yrs | no data | 15.92% CA$ 41.7m | |
| Independent Director | 2yrs | no data | no data | |
| Independent Director | 2.3yrs | no data | 15.94% CA$ 41.8m |
Experienced Board: METX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/22 01:26 |
| End of Day Share Price | 2025/06/13 00:00 |
| Earnings | 2025/02/28 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ME Therapeutics Holdings Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.